RAC1 and cancer: Given our observation that RAC1-amplified HNSCC were pharmacologically vulnerable to EHop-016, we tested the hypothesis that RAC1-amp status in other cancer, such as melanoma, might also confer sensitivity to Rac1 targeting using EHop-016.